Governance
Investors
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
Onco IX
OncoFAP Radio Conjugates
Tripokin
Press Releases & Events
Work with us
Careers
Partnering
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dekavil
Dodekin
Onco IX
OncoFAP Radio Conjugates
Tripokin
Press Releases & Events
Work with us
Careers
Partnering
Investors
Investor Relations
Shareholding
IPO
Press Releases
Financial Statements
Financial Calendar
Internal Dealing
Buyback
Analyst Coverage
Webinars
IR Contacts
Governance
Board of Directors
Board of Statutory Auditors
Documents & Procedures
Shareholders’ Meetings
Codice etico e Modello 231
Sustainability (ESG)
prova
Search for:
Recent Posts
Philogen Announces Clinical Trial Collaboration with MSD
Philogen kindly invites you to attend a virtual briefing for analysts on 5 June 2023 to discuss the Company’s latest updates.
Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand (Price Sensitive)
Sun Pharma e Philogen stipulano un Accordo di commercializzazione, Licenza e Fornitura in esclusiva per il prodotto innovativo Nidlegy™ in Europa, Australia e Nuova Zelanda (Price Sensitive)
29 maggio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
Recent Comments
Recent Comments